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Abstract 
Background: Approximately 0.8% of adults aged 18–49 in Myanmar are seropositive for Human Immunodeficiency 
Virus (HIV). Identifying the demographic, epidemiological and clinical characteristics of people living with HIV (PLHIV) 
is essential to inform optimal management strategies in this resource-limited country.
Methods: To create a “snapshot” of the PLHIV seeking anti-retroviral therapy (ART) in Myanmar, data were collected 
from the registration cards of all patients who had been prescribed ART at two large referral hospitals in Yangon, prior 
to March 18, 2016.
Results and discussion: Anti-retroviral therapy had been prescribed to 2643 patients at the two hospitals. The 
patients’ median [interquartile range (IQR)] age was 37 (31–44) years; 1494 (57%) were male. At registration, inject-
ing drug use was reported in 22 (0.8%), male-to-male sexual contact in eleven (0.4%) and female sex work in eleven 
(0.4%), suggesting that patients under-report these risk behaviours, that health care workers are uncomfortable 
enquiring about them or that the two hospitals are under-servicing these populations. All three explanations appear 
likely. Most patients were symptomatic at registration with 2027 (77%) presenting with WHO stage 3 or 4 disease. In 
the 2442 patients with a CD4+ T cell count recorded at registration, the median (IQR) count was 169 (59–328) cells/
mm3. After a median (IQR) duration of 359 (185–540) days of ART, 151 (5.7%) patients had died, 111 (4.2%) patients 
had been lost to follow-up, while 2381 were alive on ART. Tuberculosis (TB) co-infection was common: 1083 (41%) 
were already on anti-TB treatment at registration, while a further 41 (1.7%) required anti-TB treatment during follow-
up. Only 21 (0.8%) patients were prescribed isoniazid prophylaxis therapy (IPT); one of these was lost to follow-up, 
but none of the remaining 20 patients died or required anti-TB treatment during a median (IQR) follow-up of 275 
(235–293) days.
Conclusions: People living with HIV in Yangon, Myanmar are generally presenting late in their disease course, 
increasing their risk of death, disease and transmitting the virus. A centralised model of ART prescription struggles 
to deliver care to the key affected populations. TB co-infection is very common in Myanmar, but despite the proven 
efficacy of IPT, it is frequently not prescribed.
Keywords: HIV, Myanmar, Anti-retroviral therapy, Tuberculosis, Isoniazid prophylaxis therapy, Key affected 
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Background
Myanmar is a country at a critical point in its history. After 
five decades of military rule, the newly elected government 
faces enormous challenges in improving the health, welfare 
and prosperity of its people [1, 2]. The human immuno-
deficiency virus (HIV) epidemic is one of the country’s 
greatest health concerns: in 2015, 0.8% of the country’s 
adults aged 18–49 were seropositive [3]. Myanmar’s health 
system remains poorly resourced and under-equipped to 
achieve the UNAIDS “90–90–90” target or the ambitious 
Sustainable Development Goal of ending the AIDS epi-
demic by 2030 [4, 5]. HIV prevalence is highest in people 
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who inject drugs (PWID), men who have sex with men 
(MSM) and female sex workers (FSW) [6]. However, it is 
frequently challenging for Myanmar health services to 
reach these key affected populations (KAPs) and ensure 
that they are receiving optimal care [6].
One of the key aspects of the country’s response to 
the HIV epidemic has been a rapid scale up of anti-ret-
roviral therapy (ART). In 2015, 111,563 individuals—
representing an estimated 50% of the people living with 
HIV (PLHIV)—were receiving ART and the rollout has 
accelerated since [6]. All PLHIV in Myanmar receiv-
ing ART have basic demographic, epidemiological and 
clinical data collected prospectively and entered into 
the National AIDS Programme’s “Patient HIV Care and 
Antiretroviral Treatment (ART) Record”, commonly 
referred to as “The White Card”. The White Card records 
a patient’s gender, age, address and marital and employ-
ment status. It documents their referral origin, their risk 
factors for infection, the CD4+ count, the WHO disease 
stage and the presence or history of tuberculosis. It also 
records the prescribed ART regimen and if a patient dies 
or is lost to follow up.
These simple data provide a useful insight into the 
characteristics of the PLHIV receiving ART, and there-
fore might inform approaches for the optimal delivery of 
care. Just as importantly, the absence of key populations 
in these data might highlight PLHIV who are not receiv-
ing ART, permitting policy makers to develop strate-
gies to reach under-serviced populations, improving the 
health of these often vulnerable populations, and also 
preventing ongoing transmission [6–8].
This study examined White Card data collected at two 
large ART prescribing centres to create a “snapshot” of 
the HIV epidemic in Myanmar. It was hoped that this 
might both identify the successes of the current pro-
gramme and the challenges that remain.
Methods
The White Cards of all PLHIV commencing ART 
between the 6th June 2001 and the 18th March 2016 at 
two Yangon hospitals—Waibargi Hospital (a specialist 
infectious disease hospital) and Insein General Hospi-
tal (a tertiary referral general hospital)—were reviewed. 
These data were de-identified and transferred from the 
hospital databases into an electronic database (Micro-
soft Excel); statistical analysis was performed using sta-
tistical software (Stata, version 10). Death was either 
witnessed in hospital or reported by the next of kin. If 
there was no contact for 3  months after the last outpa-
tient visit, the patient was defined as lost to follow up. 
Groups were analysed using the Kruskal–Wallis and 
Chi squared tests. Multivariate analysis was performed 
using backwards stepwise logistic regression, with only 
variables that were significant in univariate analysis at a 
significance level of <0.05 selected for multivariate anal-
ysis. Ethical approval for the study was granted by the 
Human Research Ethics Committees of the University of 
Medicine 2, Yangon and the Menzies School of Health 
Research, Darwin, Australia. The Committees waived the 
requirement for informed consent as the publication of 
retrospective, aggregated, de-identified data was felt to 
pose negligible risk to the participants.
Results
There were 2643 patients with a completed white card 
at the two hospitals, 1674 at Waibargi Hospital and 
969 at Insein General Hospital; their characteristics are 
presented in Tables 1 and 2. The median [interquartile 
range (IQR)] age of the patients was 37 (31–44) years; 
1494 (57%) patients were male. Most patients were 
referred after having presented with symptoms to the 
outpatient department (1959 patients, 74%) or after 
an inpatient admission (449 patients, 17%); 68 patients 
(2.6%) presented for voluntary testing while only two 
patients (0.1%) were referred from a drug treatment 
service.
All patients had data collected on risk factors for infec-
tion: 2271 (86%) were recorded as having acquired the 
infection heterosexually, 82 (3.1%) were recorded as 
having acquired the infection from a blood transfusion. 
Only 22 (0.8%) were documented to have acquired the 
infection through injecting drug use, while male-to-male 
sexual contact was reported in eleven (0.4%) and eleven 
(0.4%) reported that they were female sex workers. Of 
the 2643 patients, 1545 (58%) were married; 664 (43%) 
had an HIV positive spouse, while in 207 (13%) cases 
the spouse was negative and in 674 (44%) the HIV status 
of the spouse was unknown. Waibargi Hospital looked 
after a greater number of patients from outside the Yan-
gon region: 30% versus 4.5% at Insein General Hospital 
(p < 0.001).
Patients generally presented late in the course of the 
disease: 2027 (77%) presented with WHO stage 3 or 4 
disease. In the 2442 patients with a CD4+  T-cell count 
recorded at registration, the median (IQR) CD4+  count 
was 169 (59–328) cells/mm3. Tuberculosis was common 
in the cohort: 1083 (41%) were already on treatment for 
tuberculosis at the time of registration, while a further 
41 (1.7%) required treatment for tuberculosis after reg-
istration. Despite the high rate of tuberculosis, only 21 
patients in the cohort were prescribed isoniazid prophy-
laxis therapy (IPT) during the study period. There were 
2627 patients with data available regarding co-trimoxa-
zole prophylaxis (CPT), 2125 (81%) of whom received this 
therapy during the study period, including 1158 (85%) of 
the 1358 patients with a CD4+ count of <200 cells/mm3.
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In the 2450 patients for whom the exact date of 
ART commencement was available, it was initiated at 
a median (IQR) of 21 (9–42) days after the HIV diag-
nosis was recorded. One hundred and seven (4.4%) 
PLHIV started ART on the same day that the diagnosis 
was recorded. The most commonly prescribed antiret-
roviral (ART) regimen was tenofovir, emtricitabine 
and efavirenz, with 2280 (86%) receiving this combi-
nation. In the 1247 patients with a recorded follow 
up CD4+  T-cell count at least 90  days after registra-
tion, there was a median increase in the CD4 count of 
150 (47–263) cells/mm3; 192 (15.1%) had a fall in their 
CD4+ count.
At the time of data analysis, a median (IQR) of 359 
(185–540) days after patient registration, 151 (5.7%) 
patients had died, 111 (4.2%) had been lost to follow up 
and 2381 (90.1%) were alive and taking ART (Table  1). 
In multivariate analysis, the independent predictors of 
Table 1 Characteristics of the patients at the two study sites
All numbers represent median and interquartile range or absolute number (percentage)
WHO World Health Organization, TDF tenofovir disoproxil fumarate, FTC emtricitabine, EFV efavirenz, ART anti-retroviral therapy
^ Comparison between the study sites using Kruskal–Wallis or Chi squared test








Age 37 (31–44) 38 (32–45) 35 (29–41) <0.001
Gender (% male) 1494 (57%) 1011 (60%) 483 (50%) <0.001
Unemployed 917 (35%) 453 (27%) 464 (48%) <0.001
Living in the same regiona 2042 (80%) 1117 (70%) 925 (95%) <0.001
CD4+ at registration 169 (59–328) 159 (50–332) 185 (74–323) 0.03
WHO stage at registration 3 (3–3) 3 (3–4) 3 (1–3) <0.001
Prescribed TDF + FTC + EFV 2280 (86%) 1420 (85%) 860 (89%) 0.005
CD4+ change after ART (cells/mm3) 148 (46–263) 141 (44–258) 166 (52–276) 0.19
Required anti-tuberculosis treatment 1124 (43%) 691 (41%) 433 (45%) 0.09
Isoniazid prophylaxis therapy 21 (0.8%) 0 21 (2%) <0.001
Co-trimoxazole prophylaxis therapy 2125 (81%) 1254 (76%) 871 (90%) <0.001
Died 151 (5.7%) 116 (7.3%) 35 (3.7%) <0.001
Lost to follow up 111 (4.2%) 89 (5.3%) 22 (2.3%) <0.001
Table 2 Comparison between patients who had died or who were alive on ART at the end of the study period
All numbers represent median and interquartile range or absolute number (percentage)
^ Comparison between survivors and those that died using Kruskal–Wallis or Chi squared test
a Does not include the 111 patients in the cohort lost to follow up
b 75 patients did not have an address recorded; 6 patients who died and 69 still alive
c One patient lost to follow up








Age 37 (31–44) 40 (33–45) 37 (31–44) 0.001
Gender (% male) 1494 (57%) 96 (64%) 1327 (56%) 0.06
Unemployed 917 (35%) 64 (42%) 814 (34%) 0.04
Living in a different regionb 526 (20%) 43 (30%) 462 (20%) 0.005
CD4 + count at registration (cells/mm3) 169 (59–328) 45 (23–127) 183 (65–337) <0.001
WHO stage at registration 3 (3–3) 4 (3–4) 3 (2–3) 0.0001
On treatment for tuberculosis 1124 (43%) 99 (66%) 971 (41%) <0.001
Isoniazid prophylaxis therapyc 21 (0.8%) 0 20 (0.8%) 0.26
Co-trimoxazole prophylaxis therapyd 2125 (81%) 136 (93%) 1904 (80%) <0.001
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death were a CD4 + count at registration of <200 cells/
mm3 (odds ratio (OR) 6.4, 95% confidence interval (CI) 
3.5–11.6, p  <  0.0001); treatment at Waibargi Hospital 
(OR (95% CI) 1.9 (1.2–2.8), p  =  0.004); unemployment 
(OR (95% CI) 1.8 (1.3–2.7) p = 0.002); age >40 years (OR 
(95% CI) 1.6 (1.1–2.4) p = 0.008) and a requirement for 
TB therapy (OR (95% CI) 1.6 (1.1–2.4) p  =  0.02). The 
only variable associated with loss to follow up in either 
univariate or multivariate analysis was treatment at Wai-
bargi Hospital (OR (95% CI) 2.4 (1.5–3.9), p < 0.001). All 
21 patients receiving IPT were being treated at IGH. Of 
these 21, one was subsequently lost to follow up but none 
of the remaining 20 died or required TB treatment dur-
ing the follow up period.
Discussion
People living with human immunodeficiency virus at 
these two large treatment centres in Myanmar are pre-
senting late in their disease course. The resulting delay in 
initiating ART increases their risk of disease and death 
and the likelihood of transmitting the virus [8, 9]. Tuber-
culosis co-infection is very common, but despite the 
proven efficacy of IPT [10]—and a strong recommenda-
tion for its prescription in WHO guidelines [11]—it was 
prescribed rarely in this cohort. The greatest burden of 
HIV in Myanmar is among PWID, MSM and FSW [6], 
however, very few patients in this cohort reported these 
risk behaviours at registration. This suggests that either 
these large ART prescribing centres are not servicing 
these KAPs, patients avoid acknowledging these risk 
behaviours or that health care workers are uncomfort-
able enquiring about them. All three explanations appear 
likely.
The late presentation of Myanmar PLHIV in this series 
resembles the findings in studies in other resource-lim-
ited settings [12–16]. Late presentation is not restricted 
to patients with HIV infection in a country whose pub-
lic health care system is critically under-resourced [2]. 
In a 2012 WHO report, Myanmar was the country with 
the lowest government spending per person per year on 
health [17] and it is sobering to reflect that these data 
were collected in Yangon, one of the better resourced 
regions in the country [18]. Meanwhile, 70% of the popu-
lation reside in rural areas, where resources and access to 
skilled health personnel are far more limited [2] and it is 
these areas—particularly the North and East of the coun-
try—where the HIV burden is greatest and programmes 
for PLHIV less developed [19–22].
The high prevalence of TB in this cohort emphasises 
the importance of integrating TB and HIV services [23] 
and brings into sharp relief the very low rates of IPT 
prescription, although the fact that co-trimoxazole was 
prescribed commonly demonstrates that there is no 
reluctance to prescribe prophylaxis per se [24]. Anecdo-
tally, many Myanmar clinicians express concerns about 
the possibility of IPT leading to the development of 
resistance or adverse drug reactions, but there is no rea-
son to think that this would occur at a higher rate than 
in other countries with a high TB prevalence where IPT 
has shown unequivocal benefit [25, 26]. While the num-
ber of patients prescribed IPT in our sample is too small 
to draw any broad conclusions, it may reassure sceptical 
Myanmar clinicians that no patients receiving IPT died 
or required TB treatment during follow-up. In a country 
where PLHIV are still presenting with advanced immu-
nodeficiency, it is hoped that there is less resistance to 
the rollout of expanded prophylaxis regimens which have 
recently been shown to reduce mortality and hospitalisa-
tion without increased serious adverse events [27].
The majority of new HIV infections in Myanmar are 
in PWID (HIV prevalence in this population in 2014: 
23.1%), MSM (HIV prevalence in 2014: 6.6%), and FSW 
(HIV prevalence in 2014: 6.3%) [6], but stigma and dis-
crimination against these populations in Myanmar 
impose substantial barriers to their access to HIV pre-
vention and care [28]. Both Waibargi and IGH are large 
hospitals running extremely busy, open-plan outpatient 
departments. While it appears likely that patients are 
under-reporting these risk behaviours and/or clinicians 
are under-documenting them, neither hospital provides 
an ideal setting for their disclosure. Unfortunately, this is 
a situation that is replicated around the country; it is esti-
mated that a significant proportion of the KAPs are not 
being reached by the National AIDS Programme (NAP) 
and its partners, and an even smaller proportion are 
being tested for HIV [28].
People who inject drugs are a particularly challeng-
ing group to reach, reflected by the fact that this group 
accounted for 39% of all new infections in 2014 [6]. The 
fact that the rates of injecting drug use are highest in 
remote—and sometimes politically unstable—areas in 
the North of the country adds another layer of complex-
ity to service delivery. However, there are positives: there 
has been a significant scaling-up of harm reduction activ-
ities, including the provision of methadone maintenance 
therapy and the possession of hypodermic needles is no 
longer illegal. Meanwhile, supportive drop-in-centres 
(DICs) continue to be the mainstay of prevention efforts 
targeting MSM and FSW, providing education, free con-
doms and outreach programmes. While support groups 
have been shown to reduce mortality and improve clini-
cal outcomes [29], they undoubtedly improve the quality 
of life of many MSM and FSW who would otherwise feel 
ostracised in what remains a conservative country. Some 
of these DICs also offer onsite health care services and 
ART access.
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The finding that outcomes were worse at Waibargi 
Hospital—a specialist infectious disease hospital—than 
IGH—a general hospital—is likely explained by the fact 
that Waibargi Hospital manages cases that are more 
complex than IGH. Indeed IGH refers its complicated 
patients with multiple comorbidities to Waibargi Hospi-
tal. Waibargi Hospital also receives more referrals from 
outside the Yangon region, which hinders optimal follow 
up care and almost certainly contributes to that hospital’s 
higher rate of loss to follow up. The association between 
unemployment—a marker of socioeconomic disadvan-
tage—and death is unsurprising, although the high rate 
of unemployment in the cohort emphasises the bidirec-
tional relationship between HIV and poverty [30].
There are positives in these data: almost 85% of 
patients who were prescribed ART had an increase in 
their CD4+ count and even with high rates of advanced 
symptomatic disease, overall survival and retention in 
care was relatively good when compared to other series 
from low and middle income countries [13, 15, 31, 32]. 
However, the reality is that Myanmar’s HIV program is 
grossly underfunded [33]. Total spending for HIV in 
Myanmar was approximately USD 84.1 million in 2015—
an increase from USD 68.9 million in 2014—but this 
programme is heavily reliant on the Global Fund, and 
current funding levels are insufficient to reach Myan-
mar’s stated objectives [34].
One of the greatest issues in the management of HIV 
in Myanmar is the profoundly under-developed state 
of laboratory services [35]. The clinical management of 
other common diseases in Myanmar—such as malaria—
requires less laboratory support [36, 37]; however, this is 
assuredly not the case with HIV. The absence of viral load 
testing in the public health system precludes early recog-
nition of poor adherence, drug malabsorption and viral 
resistance, but despite data to support its cost-effective-
ness [38], there are enormous challenges in implement-
ing viral load testing in resource-limited settings when 
even basic laboratory services are lacking [39, 40].
Our study has limitations. Although the data are col-
lected from two of the largest ART prescribing centres in 
Myanmar’s biggest city, they are not necessarily general-
isable to the entire country. There are NGOs that target—
and undoubtedly reach—KAPs more effectively and IPT 
is a key component of the care provided by these services. 
The data presented here are retrospective and relatively 
basic; to guide policy in the future, it will be important to 
collect detailed data prospectively and to link these data 
with the delivery of services and clinical outcomes. It will 
be essential to have robust quality assurance mechanisms 
to ensure that the collected data are complete, timely and 
accurate if they are to inform optimal policy.
The Myanmar National AIDS Programme (NAP) plans 
to increase access to public sector ART. It aims to achieve 
this through further decentralisation of HIV testing and 
ART prescription, transitioning to a “Test-and-Treat” 
strategy and expanded co-operation with non-govern-
ment organisations [6]. There is a particular focus on 
improving the prevention of mother-to-child transmis-
sion, and the integration of TB and HIV services. There 
is the recognition that the strengthening of laboratory 
capacity is essential if these ambitious plans are to be 
to implemented [34]. The NAP acknowledges a failure 
to reach KAPs and it is hoped that the strengthening of 
community-based support groups and the integration 
of harm reduction strategies into community-based set-
tings may improve the delivery of care to these vulnerable 
populations.
Conclusions
People living with human immunodeficiency virus at two 
of the largest ART prescription centres in Myanmar are 
presenting late in their disease course, increasing their 
risk of death and disease and the likelihood of viral trans-
mission. Although retention rates and survival were rela-
tively good at these centres, a centralised model of ART 
prescription is struggling to deliver care to the KAPs 
that bear the greatest burden of disease in the country. 
While TB co-infection is very common in Myanmar, IPT 
is frequently not prescribed despite its proven efficacy. 
Sustained political and financial commitment, health sys-
tem strengthening, reliable data collection and flexible, 
evidence-based health policies are required to build on 
recent progress in the care of PLHIV in the country.
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